This fact sheet outlines the objectives of EU public health policy and the context in which it has developed. It presents the EU’s major achievements in promoting health and preventing disease, with a focus on cancer and building resilience to infectious diseases and cross-border health threats. The public health challenges associated with demographic change are addressed, as is the need to ensure access to critical medicines. Recent policy developments in eHealth and biotechnology are also presented.

Legal basis

  • The Treaty on the Functioning of the European Union addresses public health in Article 168. Article 114 is one of the legal bases of EU legislation on the manufacture, presentation and sale of tobacco and related products, while Article 153 is the legal basis for several EU directives in the field of safety and health at work.
  • Article 35 of the Charter of Fundamental Rights of the European Union states that everyone has the right to access preventive health care and to benefit from medical treatment in national healthcare systems.
  • Objectives of EU health policy

    National governments of EU countries (EU Member States) hold primary responsibility for organising and delivering health services and medical care. EU public health policy complements national policies and aims to:

    • Protect and improve the health of people in the EU;
    • Support the modernisation and digitalisation of health systems and infrastructure;
    • Improve the resilience of the EU’s health systems; and
    • Better equip EU countries to prevent and address future pandemics.
    • How EU public health policy has evolved

      Changes to the EU’s founding Treaties in the 1990s made public health more prominent in the EU’s policies. The right to freedom of movement means that both patients and health professionals can move freely between EU Member States. In addition, major health issues often cross national borders and have social and economic consequences for the EU.

      Two specialised agencies help shape EU public health policy:

      • The European Medicines Agency was set up in 1995 to evaluate medicines, supervise their use within the EU and monitor their safety;
      • The European Centre for Disease Prevention and Control, created in 2004, collects data on infectious diseases, assesses risks and provides guidance to help countries prevent and respond to outbreaks and public health threats.
      • The EU4Health programme (2021-2027) was established to meet long-term health challenges by making health systems stronger, more resilient and more accessible. It was adopted as a response to the COVID-19 pandemic and to improve crisis preparedness in the EU. It emphasises the importance of collective resilience and cross-border health security, paving the way towards a European health union.

        The European health union is a policy framework that focuses on:

        • Preparing for future health crises and cross-border health threats;
        • Modernising the EU’s pharmaceutical laws to improve people’s access to affordable and innovative medicines;
        • Preventing and detecting cancer and providing high-quality care for cancer patients;
        • Establishing a common framework for the use and exchange of electronic health data across the EU (the European Health Data Space).
        • The EU is also concerned with global health and has recently strengthened its engagement in the field with the global health resilience initiative.

          Achievements and current developments in public health policy

          A. Health in all policies and One Health

          In 2006, the ‘health in all policies’ approach was formulated – an approach that considers the impact on health of all policies, not just those that explicitly address public health. In line with Articles 9 and 168(1) of the Treaty on the Functioning of the European Union and Article 35 of the Charter, health implications should be considered in all policymaking at EU, national and local levels.

          Recent examples show the ‘health in all policies’ approach in action:

          • The zeropollution action plan seeks to create a cleaner and healthier living environment;
          • The EU4Health programme (2021-2027), together with other funds and programmes, helps address health issues from multiple perspectives;
          • Several policies aim to prevent the harmful health effects of climate change, such as the increasing number of deaths due to heatwaves and natural disasters, changing patterns of infection in water-borne diseases, and diseases transmitted by insects, snails or other cold-blooded animals.
          • The One Health approach is an integrated, unifying approach that aims to sustainably balance and optimise the health of people, animals and ecosystems. Its concerns include the prevention of diseases transmitted directly or indirectly between animals and humans and the reduction of antimicrobial resistance (i.e. when bacteria, viruses, fungi and parasites no longer respond to medicines used to prevent or treat them).

            B. Disease prevention and health promotion

            EU initiatives in this area focus on the prevention of communicable (i.e. infectious) and non-communicable diseases, including cancer, and the reduction of antimicrobial resistance.

            1. Cancer

            Cancer is the second leading cause of death in the EU. Its impact extends beyond personal and familial spheres, as it also affects healthcare systems and economic productivity. The EU tackles cancer through several initiatives.

            • Europe’s Beating Cancer Plan, from 2021, covers prevention, early diagnosis, treatment and follow-up.
            • In 2022, the European Commission presented a new approach to cancer screening to support Member States’ efforts to boost the uptake of cancer screening. Its target was to ensure that 90% of people in the EU who qualify for breast, colorectal and cervical cancer screenings were offered screening by 2025.
            • To support policymakers and help guide investment in combating cancer, the Country Cancer Profiles highlight the achievements, challenges and disparities in cancer care across the EU.
            • The European Code against Cancer is a set of recommendations on how people in the EU can reduce their risk of cancer. The 2025 edition updates and expands prevention guidelines, integrating the latest scientific evidence and policy recommendations.
            • 2. Other non-communicable diseases

              In December 2021, the European Commission launched the ‘Healthier together – EU non-communicable diseases initiative’ to help Member States reduce the burden of major non-communicable diseases and enhance people’s well-being. Two areas are given particular attention: mental health and cardiovascular disease.

              a. Mental health and well-being

              In the EU, more than 84 million people – around one in six people – have mental health problems. Mental health has been integrated into the EU’s public health agenda through initiatives such as the Joint Action on Mental Health and Well-being (2013-2016). This led, in turn, to the creation of the European Framework for Action on Mental Health and Wellbeing.

              With suicide being the second main cause of death among 15-29-year-olds, prevention, awareness, non-stigmatisation and access to help remain of key importance. In 2023, the European Commission adopted a communication on a comprehensive approach to mental health. Mental health and neurological disorders are also supported by the ‘Healthier together’ initiative. In January 2026, a European partnership for brain health was launched.

              b. Cardiovascular disease and lifestyle factors

              Cardiovascular disease is the leading cause of death in the EU.Drugs, alcohol and tobacco consumption are lifestyle choices that significantly increase the risk of developing heart-related conditions, which have a serious impact on human health. Addressing these risk factors is a major focus of EU health policy. Milestones in regulating tobacco use include the Tobacco Tax Directive in 2011 and the Tobacco Products Directive in 2014. In July 2025, the European Commission proposed a revision of the Tobacco Taxation Directive to expand its scope to new products and increase minimum tax rates to reflect inflation and differences in price levels between Member States.

              In December 2025, the European Commission unveiled a cardiovascular health plan, the Safe Hearts Plan, which focuses on cardiovascular diseases among more vulnerable groups. Since 2025, the European Parliament has been working on an own-initiative report on an EU cardiovascular diseases strategy.

              3. Communicable diseases and public health threats

              The European Centre for Disease Prevention and Control has an early warning and response system to detect and respond to possible outbreaks of communicable diseases and cross-border threats to health.

              The EU Health Security Committee – composed of health authority representatives from the EU Member States and Iceland, Liechtenstein and Norway – coordinates the EU’s response to outbreaks and epidemics and cooperates with the World Health Organization.

              In 2022, the mandates of the European Medicines Agency and the European Centre for Disease Prevention and Control were extended, a new regulation on serious cross-border health threats was adopted, and the Health Emergency Preparedness and Response Authority (HERA) was set up to improve preparedness and response to serious cross-border threats.

              In addition, in April 2025, the European Commission launched a public consultation to inform its strategy on medical products used in response to public health emergencies. The strategy will ensure that the EU is prepared for and can respond to public health threats, including chemical, biological, radiological and nuclear threats.

              C. Societal and demographic change

              The EU faces the challenge of ensuring that its ageing population has a high quality of life and that its healthcare systems are sustainable. In 2021, the European Commission published a discussion paper on ageing, followed by a report entitled ‘The impact of demographic change in a changing environment’ in 2023. Having identified the challenges arising from ageing, population decline and a smaller workforce, it also presented policy tools for managing demographic change, in a communication entitled ‘Demographic change in Europe: a toolbox for action’.

              Migration crises also present challenges for public health policy. The European Commission published its action plan on the integration of non-EU nationals in 2016. It addresses the health-related disadvantages experienced by migrants, including difficulty accessing healthcare. In 2020, the European Commission put forward the European Agenda on Migration and the Pact on Migration and Asylum, with the aim of further streamlining EU policies in this area. New regulations will be applicable from 1 July 2026.

              With the aim of reducing childhood inequalities in areas such as health, a European Childhood Guarantee was adopted in 2021. Its aim is to prevent and combat social exclusion by ensuring effective access to key services, including free healthcare and healthy nutrition. As a first step, Member States submitted national plans outlining how they will implement the European Child Guarantee up to 2030. In February 2026, the European Parliament proposed the aim of eradicating child poverty by 2035.

              D. Medicines

              A medicinal product (medicine) is a substance or combination of substances that is used for the treatment or prevention of diseases in human beings (see 2.2.5). The EU has passed several laws to regulate how medicinal products are authorised, marketed and used in the EU. They include:

              • A 2001 directive on the authorisation, manufacturing, importing and marketing of medicinal products (Directive 2001/83/EC);
              • A 2004 regulation setting out procedures for authorising medicinal products and rules for monitoring them, and establishing the European Medicines Agency (Regulation (EC) No 726/2004).
              • A significant development was the adoption of the ‘pharma package’, aiming to make medicines more available, more accessible and more affordable. The purpose of the package is to better meet patient needs by boosting innovation and competitiveness through incentives for the development of new antimicrobials, medicines for rare diseases and treatments for children. The package also seeks to strengthen the security of supply, ensuring the timely availability of safe and affordable medicines across the EU.

                The Critical Medicines Act, which was proposed by the European Commission in March 2025 and on which the European Parliament, the Council of the EU and the European Commission are currently negotiating, aims to improve the availability, supply and production of critical medicines.

                E. eHealth

                The EU is in the middle of a digital transformation of its healthcare systems. Digital technologies and information management systems are being integrated into various aspects of the healthcare industry. They include electronic health records, telemedicine, wearable devices, mobile apps, data analytics and other digital tools. The digitalisation of the healthcare sector is part of the EU’s digital single market strategy, which aims to align the legal frameworks and infrastructure for digital systems across the Member States.

                The eHealth Network is a voluntary network set up under a directive on patients’ rights in cross-border healthcare. It provides a platform to connect national authorities responsible for eHealth.

                In 2018, the European Commission set out its priorities for the digital transformation of health and care. They included secure access to health data for people across the EU, personalised medicine, better research through shared data infrastructure, and the empowerment of individuals through digital tools for patient feedback and person-centred care.

                The eHealth Digital Service Infrastructure ensures that people from one Member State can continue to receive care while travelling in other Member States.

                In March 2025, the regulation for a European Health Data Space entered into force. This aims to empower individuals in the EU to access and manage their own health data. It also enables health data to be reused across borders, for research and innovation, while ensuring compliance with data protection rules. This is a major achievement in the EU’s eHealth agenda. Between now and March 2027, the European Commission is set to adopt several key legal acts to specify the rules for implementing the regulation.

                F. Health technology assessment

                Health technologies include medicines, medical devices, diagnostic tools, surgical procedures and measures for disease prevention, diagnosis or treatment. Health technology assessment is a systematic evaluation of evidence-based data on health technologies. It is used to ensure that health policies are safe, effective, patient-focused and cost-efficient. It also measures the added value of health technologies, guiding national decisions about reimbursing costs for users. A regulation on assessing health technologies was adopted in 2021 and has been gradually applied since January 2025.

                G. The Biotech Act and European competitiveness

                In December 2025, the European Commission proposed the Biotech Act, which aims to accelerate innovation in health technology assessment, clinical trials and biomanufacturing, in order to strengthen European competitiveness and advance healthcare solutions. It is currently being scrutinised and discussed by the European Parliament’s Committee on Public Health and its Committee on Industry, Research and Energy. The European Commission is generally placing competitiveness at the heart of its economic agenda to address growing challenges such as climate change, AI and geopolitical tensions. In its 2026 work programme, it announced a Biotech Act II, which is expected to be proposed in late 2026.

                Role of the European Parliament

                From 2023 to 2025, the European Parliament’s public health committee operated as a subcommittee of the Committee on the Environment, Public Health and Food Safety. In February 2025, it became a full standing committee, the Committee on Public Health, no longer dependent on the parent committee. It can outline its legislative priorities and respond to legislative proposals through the adoption of reports, propose amendments to plenary and appoint a negotiation team to conduct negotiations with the Council of the EU on legislation. It is responsible for programmes and actions in public health, pharmaceutical and medical devices, health crisis preparedness and response, and mental health and patients’ rights. It also oversees the work of the European Medicines Agency and the European Centre for Disease Prevention and Control. It liaises regularly with the World Health Organization.

                This fact sheet is prepared by the European Parliament’s Policy Department for Transformation, Innovation and Health. For more information on this topic, please see the website of the Committee on Public Health.

                 

                Anne-Marie Finnemann / Ioana-Alice POSTU